ClinicalTrials.gov
ClinicalTrials.gov Menu

Retrospective, Non-significant Risk, Deep Brain Stimulation (DBS) Care Management Software Feasibility Study (DBS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01750242
Recruitment Status : Completed
First Posted : December 17, 2012
Results First Posted : September 17, 2014
Last Update Posted : September 17, 2014
Sponsor:
Information provided by (Responsible Party):
MedtronicNeuro

Brief Summary:
To evaluate DBS device settings and match with the features of the DBS care management software.

Condition or disease Intervention/treatment
Parkinson's Disease Device: Medtronic DBS system

Detailed Description:
This is a study done on Parkinson disease subjects who have received the DBS system implanted in their subthalamic nucleus.

Study Type : Observational
Actual Enrollment : 20 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: OPTIVISE Map Concordance Study in DBS for Parkinson's Disease
Study Start Date : November 2012
Actual Primary Completion Date : May 2013
Actual Study Completion Date : August 2013

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Group/Cohort Intervention/treatment
Parkinson's disease Subjects
Subjects with advanced Parkinson's Disease implanted with Medtronic DBS system in the subthalamic nucleus (STN).
Device: Medtronic DBS system
Advanced Parkinson's disease patients implanted with the Medtronic Deep Brain Stimulation (DBS) system.



Primary Outcome Measures :
  1. To Characterize the Percentage of Leads in Which the Target Map and the Clinically-derived Activation Map Overlap [ Time Frame: 18 months ]
    The one-sided 95% exact binomial lower confidence bound of the proportion was calculated from subjects with readable images enrolled in the study.


Secondary Outcome Measures :
  1. Additional Study Measure on Unified Parkinson's Disease Rating Scale (UPDRS) III Scores [ Time Frame: Change from baseline to 18 months ]
    The summary of UPDRS III medication off score at baseline and the UPDRS III stimulation on/medication off score at follow-up and the change from baseline to 18 months. The UPRS III has a range of 0 - 108.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Parkinson's disease patients who have been implanted with the DBS system
Criteria

Inclusion Criteria:

  • Patient with Medtronic Deep Brain Stimulation therapy for idiopathic levodopa responsive Parkinson's Disease
  • Patient who has had lead placement in the Subthalamic nucleus
  • Patient with pre-op MRI available
  • Patient with post-op CT scan available showing placement of the lead
  • Patient who has documented improvement of at least 35% on UPDRS III scores from baseline preoperative off medication state compared to post DBS implant stimulation on/medications off

Exclusion Criteria:

  • Patient who has had clinically significant persistent stimulation related adverse effects
  • Patient who has evidence of lead migration without lead revision
  • Patient with other brain malformations that would make it difficult to process images (ablative surgery in the basal ganglia, resective surgery, brain tumor)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01750242


Locations
United States, California
Scripps Clinic, Division of Neurology
La Jolla, California, United States, 92037
United States, Kansas
Parkinson's Disease and Movement Disorder Center, University of Kansas Medical Center
Kansas City, Kansas, United States, 66160
Sponsors and Collaborators
MedtronicNeuro
Investigators
Principal Investigator: Rajesh Pahwa, MD Parkinson's Disease and Movement Disorder Center, University of Kansas Medical Center
Principal Investigator: Melissa Houser, MD Scripps Clinic Division of Neurology

Responsible Party: MedtronicNeuro
ClinicalTrials.gov Identifier: NCT01750242     History of Changes
Other Study ID Numbers: 1669
First Posted: December 17, 2012    Key Record Dates
Results First Posted: September 17, 2014
Last Update Posted: September 17, 2014
Last Verified: September 2014

Additional relevant MeSH terms:
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases